Dose-Dense Therapy in Aggressive Lymphoma
- Conditions
- Lymphoma
- Registration Number
- NCT00517894
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Brief Summary
To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.
- Detailed Description
Patients are randomized to receive dose-dense CEOP/IMVP-Dexa chemotherapy or standard 3-weekly CHOP.
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- 18 and 70 years of age
- Centrally reviewed, histologically proven diffuse large B-cell, anaplastic large-cell, or peripheral T-cell unspecified
- Measurable disease
- All stages
Exclusion Criteria
- Lymphoblastic or Burkitt histology
- CNS-disease
- HIV-positive
- pregnant or lactating women
- Pretreatment
- Other malignancy
- Concomitant diseases that forbid chemotherapy
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method